Background and Aims: Finerenone, a nonsteroidal MR antagonist (MRA), enhances renal and cardiovascular outcomes in patients with type 2 diabetes (T2DM). Finerenone’s safety and effectiveness in renal function are debatable. This meta-analysis evaluates the efficacy and safety of treatments for patients with diabetic kidney disease.Methods: To find relevant RCTs, the databases PubMed, Embase, and Google Scholar were searched. Finerenone’s effects were quantified using estimated pooled mean differences (MDs) and relative risks with 95% confidence intervals (CIs).Results: This meta-analysis combines seven double-blind trials involving patients with CKD and type 2 diabetes who were randomly assigned to finerenone or placebo. The primary efficacy time-to-event outcomes were cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, heart failure hospitalization, kidney failure, a sustained 57% decrease in estimated glomerular filtration rate from baseline over 4 weeks, or renal death. In this meta-analysis of 39,995 patients, treatment with Finerenone was associated with a lower risk of death due to cardiovascular and renal outcomes than placebo (RR = 0.86 [0.80, 0.93] p=0.0002; I2= 0%) and (RR = 0.56 [0.17, 1.82] p=0.34; I2= 0%), respectively. Finerenone treatment was also associated with a marginally lower risk of serious adverse events (RR = 0.95 [0.92, 0.97] p 0.0001; I2= 0%), but no overall difference in the risk of adverse events was found between the two groups (RR = 1.00 [0.99, 1.01] p=0.56; I2= 0%).Conclusion: The administration of finerenone decreases the likelihood of end-stage kidney disease, renal failure, cardiovascular death, and hospitalization. Therefore, we propose that patients with T2DM and CKD undergo finerenone therapy.Keywords: Diabetes, Chronic kidney disease, CKD, Cardiovascular disease, Finerenone, Non-steroidal Mineralocorticoid receptor antagonist, Meta-analysis.

Background: Ventricular Tachycardia is a life threating arrhythmia with large admission rate. In this analysis, we aim to investigate the impact of anemia in patients admitted due to ventricular tachycardia in terms of mortality, length of stay and total hospital charges. Methods: This is an analysis of the National Inpatient Sample Database of the years 2016-2020. Patients admitted with a primary diagnosis of ventricular tachycardia, with or without a secondary diagnosis of anemia were identified using the ICD-CM codes. The primary outcome was mortality. Secondary outcomes were length of stay and resources utilization. Multivariate logistic analysis was performed, and outcomes were adjusted by age, gender, race, Charlson comorbidity index, hospital location, size, region, teaching status and insurance. Data was considered statistically significant with p-value <0.05. Results: Among 221720 patients who had a primary diagnosis of ventricular tachycardia, 17.56% had anemia. Adjusted mortality was significantly different in patients with secondary diagnosis of any anemia with odds ratio 1.95, p value < 0.001, 95% Confidence Interval 1.73 – 2.2. In terms of Length of Stay, patients with anemias of any type stayed 3.09 more days in the hospital, p value < 0.001, 95% Confidence Interval 2.78 - 3.41. Patients with anemia also had an increase on their total hospital charges by 61507.92, p value < 0.001, 95% Confidence Interval 53771.36 - 69244.48. Conclusion: Patients with anemia had 1.95 higher mortality rate, stayed 3.09 more days in the hospital and had a total hospital cost higher by 61507.92$. Anemia can be a risk marker within patients admitted with ventricular tachycardia, more studies needed to investigate if the treatment of anemia improves the outcome.